BUMC Thrombotic Microangiopathy Collaborative (BUTMAC)
The Boston University Thrombotic Microangiopathy Collaborative (BUTMAC) provides a multidisciplinary approach to the care of patients with TMA. The multidisciplinary team is very unique in its structure and function, involving physicians from different subspecialties with great interest and expertise in managing patients with TMA.
The Collaborative combines basic and clinical research to advance the understanding of the TMA syndromes. We are integral part of the Affinity Research Collaborative (ARC) on Thrombosis and Homeostasis that consists of investigators from several academic departments with a common goal to investigate thrombosis in humans (http://www.bumc.bu.edu/evanscenteribr/the-arcs/the-arcs/).
- Evaluation, management and treatment of patients with TMA.
- To educate other health providers and increase awareness of the TMA syndromes
- Center for clinical trials and basic research on TMA syndromes.
- Role model for the management of patients with TMA through a multidisciplinary team approach.
Patients Frequently Asked Questions
What types of TMA syndromes do you treat at BUTMAC?
We have the clinical expertise to manage all types of TMA syndromes. Our team is very well suited to provide exceptional care without exception to all patients with TMA regardless of the underlying etiology. Our scope of expertise covers acute or chronic forms of TMA, and primary or secondary causes of TMA. Please contact our center for an appointment and we will work with you and your doctors to have you meet our team of experts as quickly as possible.
Types of TMA
What will happen on my visit?
We often ask you to send all your medical records before your visit, as this will give us enough time to review your chart and records prior to your first visit. This would allow us to spend more time with you on the day or your visit.
You will meet one or more members of our TMA team on your visit, and the team will meet after your visit to review your chart and all the workup and decide in a multidisciplinary approach on the best plan of your care.
How do I schedule an appointment at BUTMAC?
I already have a physician caring for my TMA, can I still see him? Will you communicate with my other providers?
We are delighted to work with you and your treating physician to achieve the best clinical outcomes. You can see us one time or frequently and on as needed basis while you continue to follow with your doctor/s. We will make sure that all communications are delivered at time. We have a team approach for the management of TMA and we consider you and all your doctors a part of this team. We believe that communication is crucial for the management of TMA cases due to the complexity and the seriousness of the disease.
What therapeutic options are available to treat my TMA?
We provide a variety of therapeutic options for the management of TMA. The treatment will depend essentially on the underlying cause of your TMA. Our team members are experts in kidney and hematological diseases, and they provide the state of the art treatment for most of the TMA syndromes.
BMC has been selected as a clinical site for ALEXION-funded (ALXN1210-aHUS-311) single arm, multi-center clinical trial, which examines the efficacy of the long acting recombinant anti-C5 humanized monoclonal antibody for atypical HUS. Clinical recruitment will begin soon. Investigators include Drs. Francis, Gordon and Chitalia.
For referring physicians
The BUTMAC is committed to provide a high quality of care without exception to all patients with TMA. Our TMA team has a great experience in managing patients with TMA. Our goal is to maintain the highest standards of patient care based on collegiality and continuous communication with referring physicians. Our team members are readily available to respond to referring physician requests and questions at any time via phone, or electronic mail regardless of having seen the patient or not. Our TMA center is involved in TMA clinical trials to keep advancing the understanding, management and treatment of this complex disease. Please contact Dr. Jean Francis at Jean.Francis@bmc.org and Dr. Vipul Chitalia at Vipul.Chitalia@bmc.org.